BAXTER INTL INC shareholders Q3 2023

BAXTER INTL INC's ticker is BAX and the CUSIP is 071813109. A total of 885 filers reported holding BAXTER INTL INC in Q3 2023. The put-call ratio across all filers is 0.40 and the average weighting 0.2%.

BAXTER INTL INC shareholders Q3 2023
NameSharesValueWeighting ↓
Kathleen S. Wright Associates Inc. 100$3,7740.00%
MARK SHEPTOFF FINANCIAL PLANNING, LLC 100$3,7740.00%
D. E. Shaw & Co., Inc. 53,900$2,034,1860.00%
SIMPLEX TRADING, LLC 71,660$2,7040.00%
Penserra Capital Management LLC 2,836$1060.00%
Allspring Global Investments Holdings, LLC 31,318$1,181,9410.00%
Blue Trust, Inc. 2,511$1150.00%
Sugarloaf Wealth Management, LLC 186$7,0200.00%
CI INVESTMENTS INC. 10,225$3860.00%
Assenagon Asset Management S.A. 14,746$556,5140.00%
CITIGROUP INC 75,000$2,830,5000.00%
Versant Capital Management, Inc 154$5,8120.00%
FAYEZ SAROFIM & CO 13,686$516,5100.00%
Cerity Partners LLC 9,703$366,3540.00%
NORTHWESTERN MUTUAL WEALTH MANAGEMENT CO 37,475$1,414,3130.00%
Luken Investment Analytics, LLC 74$2,7930.00%
RVW Wealth, LLC 399$15,0580.00%
Legacy Financial Group LLC 217$8,190,0000.00%
Pacifica Partners Inc. 100$3,7020.00%
TIAA TRUST, NATIONAL ASSOCIATION 16,261$613,6900.00%
About BAXTER INTL INC

Baxter International Inc. is a global healthcare company that specializes in developing and manufacturing medical products and therapies. The company has a long history of innovation and has been at the forefront of developing life-saving treatments for patients around the world.

Baxter's product portfolio includes a wide range of medical devices, pharmaceuticals, and biotechnology products. The company's products are used in hospitals, clinics, and other healthcare settings to treat a variety of conditions, including hemophilia, immune disorders, kidney disease, and other chronic and acute medical conditions.

Baxter's commitment to innovation has helped the company maintain a strong position in the healthcare industry. The company invests heavily in research and development, and has a strong pipeline of new products in development.

Baxter's leadership team is also a key strength of the company. The CEO, José Almeida, has a strong track record of success in the healthcare industry, and has been instrumental in driving the company's growth and success.

Overall, Baxter International Inc. is a strong and innovative company that is well-positioned to continue delivering value to patients, healthcare providers, and investors alike. With a strong product portfolio, a commitment to innovation, and a talented leadership team, Baxter is a company that investors should keep an eye on in the years to come.

It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.

External links

This page lists BAXTER INTL INC's shareholders in Q3 2023. To view BAXTER INTL INC's shareholder history, click here.